Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher P Fox

Showing results (31-40 of 127) with videos related to

Pageof 13
Sort By:
Journal of Hematology & Oncology|September 8, 2021
Matching-adjusted indirect treatment comparison of liso-cel versus axi-cel in relapsed or refractory large B cell lymphomaDavid G Maloney, John Kuruvilla, Fei Fei Liu, et al.
Leukemia & Lymphoma|September 8, 2020
A comparison of bendamustine-EAM versus BEAM conditioning for autogolous stem cell transplant in lymphomaAlexander Glover, Christopher P Fox, Andrew McMillan, et al.
British Journal of Haematology|November 21, 2022
Management of secondary central nervous system lymphomaKate Cwynarski, Thomas Cummin, Wendy Osborne, et al.
Journal of Cancer Research and Clinical Oncology|October 2, 2024
A European consensus recommendation on the management of delayed methotrexate elimination: supportive measures, leucovorin rescue and glucarpidase treatmentStefan S Bielack, Carole Soussain, Christopher P Fox, et al.
British Journal of Haematology|September 5, 2025
Clinical management of bispecific antibody therapy for lymphoma: A British Society for Haematology Good Practice PaperSridhar Chaganti, Vaishali Dulobdas, Matthew R Wilson, et al.
Experimental Hematology & Oncology|March 26, 2022
Matching-adjusted indirect treatment comparison of chimeric antigen receptor T-cell therapies for third-line or later treatment of relapsed or refractory large B-cell lymphoma: lisocabtagene maraleucel versus tisagenlecleucelGuillaume Cartron, Christopher P Fox, Fei Fei Liu, et al.
Clinical Lymphoma, Myeloma & Leukemia|September 3, 2025
Indirect Comparison of Epcoritamab Versus Axicabtagene Ciloleucel in Chimeric Antigen Receptor T-Cell-Eligible and -Naive Patients With Relapsed/Refractory Diffuse Large B-Cell LymphomaGilles Salles, Christopher P Fox, Mehdi Hamadani, et al.
British Journal of Haematology|November 23, 2021
Guidelines for the management of mature T- and natural killer-cell lymphomas (excluding cutaneous T-cell lymphoma): a British Society for Haematology GuidelineChristopher P Fox, Matthew J Ahearne, Ruth Pettengell, et al.
Ejhaem|October 17, 2024
Real-world outcomes of patients with relapsed/refractory large B-cell lymphoma receiving second-line therapy in EnglandChristopher P Fox, William Townsend, John G Gribben, et al.
Journal of Personalized Medicine|July 29, 2023
Early MRI Predictors of Relapse in Primary Central Nervous System Lymphoma Treated with MATRix ImmunochemotherapyIsabel Cornell, Ayisha Al Busaidi, Stephen Wastling, et al.
Pageof 13

Showing results (31-40 of 127) with videos related to

Sort By:
Pageof 13
Journal of Hematology & Oncology|September 8, 2021
Matching-adjusted indirect treatment comparison of liso-cel versus axi-cel in relapsed or refractory large B cell lymphomaDavid G Maloney, John Kuruvilla, Fei Fei Liu, et al.
Leukemia & Lymphoma|September 8, 2020
A comparison of bendamustine-EAM versus BEAM conditioning for autogolous stem cell transplant in lymphomaAlexander Glover, Christopher P Fox, Andrew McMillan, et al.
British Journal of Haematology|November 21, 2022
Management of secondary central nervous system lymphomaKate Cwynarski, Thomas Cummin, Wendy Osborne, et al.
Journal of Cancer Research and Clinical Oncology|October 2, 2024
A European consensus recommendation on the management of delayed methotrexate elimination: supportive measures, leucovorin rescue and glucarpidase treatmentStefan S Bielack, Carole Soussain, Christopher P Fox, et al.
British Journal of Haematology|September 5, 2025
Clinical management of bispecific antibody therapy for lymphoma: A British Society for Haematology Good Practice PaperSridhar Chaganti, Vaishali Dulobdas, Matthew R Wilson, et al.
Experimental Hematology & Oncology|March 26, 2022
Matching-adjusted indirect treatment comparison of chimeric antigen receptor T-cell therapies for third-line or later treatment of relapsed or refractory large B-cell lymphoma: lisocabtagene maraleucel versus tisagenlecleucelGuillaume Cartron, Christopher P Fox, Fei Fei Liu, et al.
Clinical Lymphoma, Myeloma & Leukemia|September 3, 2025
Indirect Comparison of Epcoritamab Versus Axicabtagene Ciloleucel in Chimeric Antigen Receptor T-Cell-Eligible and -Naive Patients With Relapsed/Refractory Diffuse Large B-Cell LymphomaGilles Salles, Christopher P Fox, Mehdi Hamadani, et al.
British Journal of Haematology|November 23, 2021
Guidelines for the management of mature T- and natural killer-cell lymphomas (excluding cutaneous T-cell lymphoma): a British Society for Haematology GuidelineChristopher P Fox, Matthew J Ahearne, Ruth Pettengell, et al.
Ejhaem|October 17, 2024
Real-world outcomes of patients with relapsed/refractory large B-cell lymphoma receiving second-line therapy in EnglandChristopher P Fox, William Townsend, John G Gribben, et al.
Journal of Personalized Medicine|July 29, 2023
Early MRI Predictors of Relapse in Primary Central Nervous System Lymphoma Treated with MATRix ImmunochemotherapyIsabel Cornell, Ayisha Al Busaidi, Stephen Wastling, et al.
Pageof 13